Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
Clinical trial NCT04975997 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04975997
- Sponsor
- Celgene
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2022-06-23
- Primary completion
- 2027-11-16
- Enrollment
- 939
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.